NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date and time:** Wednesday 7 July 2021 – 9am to 17:30pm

**Location:** Zoom video conference

## Attendees

Committee members present

1. Professor Amanda Adler (Chair) Present for all items
2. Dr Sanjeev Patel (Vice Chair) Present for all items
3. Dr Carlo Berti Present for all items
4. Ms Maria Bretzitski Present for items 1 to 7
5. Dr Laura Bojke Present for all items
6. Mr Mark Chapman Present for all items
7. Professor Iolo Doull Present for all items
8. Dr James Fotheringham Present for all items
9. Dr Mark Glover Present for all items
10. Dr Megan John Present for items 1 to 6
11. Dr Nicholas Latimer Present for all items
12. Dr Rhiannon Owen Present for all items
13. Ms Anna Pracz Present for all items
14. Mr Peter Wheatley Price Present for all items
15. Mr Gabriel Rogers Present for all items
16. Dr Toby Smith Present for all items
17. Mary Weatherstone Present for all items
18. Professor Nicky Welton Present for all items
19. Mr Nigel Westwood Present for all items
20. Mr Tony Wootton Present for all items

NICE staff present

Nicole Elliott, Associate Director Present for all items

Jo Ekeledo, Project Manager Present for items 1 to 6

Shonagh D’Sylva, Project Manager Present for items 6 to 8

Yelan Guo, Technical Advisor Present for items 1 to 5

Aminata Thiam, Technical Analyst Present for items 1 to 5

Charlie Hewitt, Technical Advisor Present for items 5 to 6

Emily Leckenby, Technical Analyst Present for items 5 to 6

Ross Wilkinson, Assistant Technical Analyst Present for items 5 to 6

Carl Prescott, Technical Advisor Present for items 6 to 7

Harsimran Sarpal, Technical Analyst Present for items 6 to 7

Ewa Rupniewska, Technical Advisor Present for items 6 to 8

Heidi Livingstone, Public Involvement Advisor Present for items 1 to 4.2 & 5 to 5.2

Philip Williams, Business Analyst, RIA Present for all items

Ella Livingstone, Technical Advisor Present for items 6 to 8

Emily Eaton Turner, Technical Advisor Present for items 6 to 8

Benjamin Pearce, Senior Medical Editor Present for items 1 to 5

Olivia Havercroft, Senior Medical Editor Present for items 6 to 7

Sandra Robinson, Assistant Project Manager Present for items 5 to 5.2

Nicholas Cunningham, Coordinator Present for items 1 to 4.2 & 6 to 6.2

Lucinda Evans, Coordinator Present for items 1 to 4.2 & 6 to 6.2

Emma Gordon. Administrator Present for items 1 to 6

Lucy Ingram, Administrator Present for items 6 to 8

Sophie McHugh, Administrator Present for all items

Pratit Shah, Administrator Present for items 5 to 6

Hollie Kemp, Apprentice Present for items 1 to 5

Evidence Review Group representatives present

Rob Riemsma, Reviews Manager, Kleijnen Systematic Reviews Present for items 1 to 4.3

Hannah Penton, Health Economics Researcher, Kleijnen Systematic Reviews Present for items 1 to 4.3

Joanne Lord, Health Economist, Southampton HTA Centre Present for items 5 to 5.3

Lorna Hazell, Senior Research Assistant, Southampton HTA Centre Present for items 5 to 5.3

Keith Cooper, Senior Research Fellow, Aberdeen HTA Present for items 6 to 6.3

Prof Jonathan Shephard, Principal Research Fellow, Aberdeen HTA Present for items 6 to 6.3

Irina Tikhonova, Senior Research Fellow, Aberdeen HTA Present for items 6 to 6.3

Experts present

Dr Anna Murphy, Consultant Respiratory Pharmacist, Present for items 1 to 4.2

 Glenfield Hospital, nominated by UK Clinical Pharmacy

 Association.

Dr Voon Ong, Consultant Rheumatologist, Royal Free Present for items 1 to 4.2

 Hospital, nominated by British Society for Rheumatology

Dr Lisa Spencer, Consultant Respiratory Physician, Present for items 1 to 4.2

 Liverpool University Hospitals, nominated by Boehringer

 Ingelheim

Mr Stephen Jones, Chair of Trustees at Action for Present for items 1 to 4.2

 Pulmonary Fibrosis (APF), nominated by APF

Mrs Debbie Roots, Cardiorespiratory Nurse Consultant, Present for items 1 to 4.2

 Association of Respiratory Nurse Specialists (ARNS)

 and Homerton University Hospital, nominated by ARNS

Professor Peter Clark, CDF Clinical Lead, NHSE&I Present for items 5 to 8

Dr Neil Rabin, Consultant Haematologist at UCL and Present for items 5 to 5.2

 Vice Chair of UK Myeloma Forum, nominated by UK

 Myeloma Forum

Dr Karthik Ramasamy, Consultant Haematologist, Present for items 5 to 5.2

 Oxford University Hospital, nominated by Janssen

Ms Shelagh McKinlay, patient expert, Head of Patient Present for items 5 to 5.2

 Advocacy at Myeloma UK, nominated by UK Myeloma

 Forum

Mrs Rosie Dill, patient expert, nominated by Myeloma UK Present for items 5 to 5.2

Observers present

Sarah Wilkes, Technical Analyst, NICE Present for all items

Rebecca Thomas, Technical Analyst, NICE Present for items 1 to 5 & 6 to

Dr Charles Crawley, Haematologist, Addenbrookes Present for all items

Ivan Koychev, Psychiatrist, Oxford University Hospitals NHS Foundation Trust, Present for items 1 to 5

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Dr Veline L’Esperance, Professor Sarah Wild and Dr Stuart Williams.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on 9 June 2021

### Appraisal of Nintedanib for treating progressive fibrosing interstitial lung disease [ID1599]

* 1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Boehringer Ingelheim.
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr James Fotheringham, committee member, declared a direct financial interest as he received consultancy and speaker fees from Novartis for promotional activity around a risk prediction tool they are using for a trial currently underway in kidney transplantation. Novartis is a comparator company for this topic. It was agreed that this declaration did not prevent Dr Fotheringham from participating in this section of the meeting.
* Dr Nicholas Latimer, committee member, declared a non-financial professional and personal interest as he is a member of the ScHARR team working on an ongoing consultancy project involving the adjustment for treatment switching observed in the NETTER-1 trial, comparing lutathera to best supportive care alone in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumours. Lutathera is made by Advanced Accelerator Applications (AAA) Ltd, a Novartis company. Novartis is a comparator company for this topic. It was agreed that this declaration did not prevent Dr Latimer from participating in this section of the meeting.
* Dr Lisa Spencer, clinical expert, declared a non-financial professional and personal interest as she contributed to discussions at an advisory board meeting for Boehringer Ingelheim in November 2020. The meeting involved discussing their submission for this Single Technology Appraisal. Dr Spencer contributed voluntarily and did not accept any fee for her involvement. Dr Spencer declared a further non-financial professional and personal interest as she is the current Honorary Secretary of the British Thoracic Society. It is the specialist society for respiratory consultants in the UK and is also a charity, of which Dr Spencer is a Trustee. This is an unpaid voluntary national position. It was agreed that these declarations did not prevent Dr Spencer from providing expert advice to the committee.
* Mr Stephen Jones, patient expert, declared an indirect interest as he has participated in various events and activities run by pharmaceutical companies. The honoraria for this involvement is paid directly to Action for Pulmonary Fibrosis or the European IPF and Related Disorders Federation (EU-IPFF) and Mr Jones does not personally benefit. Mr Jones also declared a non-financial professional and personal interest as he is the Chair of Action for Pulmonary Fibrosis, President of EU-IPFF (European IPF and Related Disorders Federation), a grouping of 21 patient organisation from 15 European countries) and a member of the Council of the European Lung Foundation. It was agreed that these declarations did not prevent Mr Jones from providing expert advice to the committee.
* Mrs Debbie Roots, patient expert, declared a non-financial professional and personal interest as she will be conducting a talk for Action Pulmonary Fibrosis on oxygen. The talk is sponsored by Boehringer Ingelheim but is unpaid and Mrs Roots is not working directly with the company. It was agreed that this declaration did not prevent Mrs Roots from providing expert advice to the committee.
	+ 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Mark Glover, Dr Nicholas Latimer and Mr Tony Wootton.
	1. Part 2a – Closed session (Members of the public, company representatives and professional experts were asked to leave the meeting. External group representatives remained).
		1. The committee discussed confidential information submitted for this item.
	2. Part 2b – Closed session (external group representatives were asked to leave the meeting).
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD). The committee decision was reached by consensus..
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

### Appraisal of Daratumumab in combination for untreated multiple myeloma when stem cell transplant is suitable [ID1510]

* 1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Janssen.
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Prior to the meeting, Mr Peter Wheatley-Price, committee member, declared a direct financial interest as his employer, Takeda, manufacture ixazomib which is used with lenalidomide and dexamethasone in a variety of indications in multiple myeloma. It recently completed a trial for newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant but does not yet have a licence. It was agreed that these declarations did not prevent Mr Wheatley-Price from participating in this section of the meeting.
* Prior to the meeting, Dr Karthik Ramasamy, clinical expert, declared direct financial interests as he received research grants and speaker honoraria from Janssen. He also partook in a paid advisory board for Janssen. During the meeting, Dr Ramasamy declared further direct financial interests as he received speaker fees from Celgene, Amgen and Takeda. He also declared an indirect interest as his Trust received research grants from Janssen for running clinical trials. It was agreed that these declarations would not prevent Dr Ramasamy from providing expert advice to the committee.
* Dr Neil Rabin, clinical expert, declared several direct financial interests as he received financial support to attend conferences from BMS/Celgene, Janssen and Takeda. He was paid to speak at educational meetings by BMS/Celgene, Janssen, Takeda and Sanofi. Dr Rabin also partook in paid advisory boards for BMS/Celgene, Janssen, Takeda, Sanofi, Karyopharm and Amgen. Dr Rabin declared a non-financial professional and personal interest as he is an executive member of the UK Myeloma Forum. It was agreed that these declarations would not prevent Dr Rabin from providing expert advice to the committee.
* Ms Shelagh McKinlay, patient expert, declared indirect interests as her employer, Myeloma UK, receives funding from Janssen and other comparator companies. Janssen has also paid for Ms McKinlay to be involved with advisory boards. All monies go directly to Myeloma UK and Ms McKinlay does not personally benefit from these funds. It was agreed that these declarations would not prevent Ms McKinlay from providing expert advice to the committee.
* Prior to the meeting, Dr Charles Crawley, observer, declared a direct financial interest as he received financial support to attend the 2020 American Society of Haematology in Dec 2020 from Janssen (value £300). It was agreed these declarations would not prevent Dr Crawley from observing this section of the meeting.
	+ 1. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Professor Amanda Adler.
	1. Part 2a – Closed session (members of the public, company representatives & professional experts were asked to leave the meeting. The evidence review group remained).
		1. The committee discussed confidential information submitted for this item.
	2. Part 2b – Closed session (external group representatives were asked to leave the meeting)
		1. The committee asked the NICE technical team to prepare the documents in line with their decisions and further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10449>

### Appraisal of Appraisal of Apalutamide for treating prostate cancer [ID1534]

* 1. Part 1 – Open session
		1. The Chair welcomed the invited members of the public and company representatives from Janssen.
		2. The Chair asked all committee membersand NICE staff present to declare any relevant interests in relation to the item being considered.
* Mr Peter Wheatley-Price, committee member, declared a direct financial interest as his employer, Takeda, sells leuprorelin which is used in the hormonal stage of prostate cancer. It was agreed that this declaration did not prevent Mr Wheatley-Price from participating in this section of the meeting.
* Dr Nicholas Latimer, committee member, declared a direct financial interest as he provided advice to Ferring, a comparator company, on the economic modelling for rebyota for clostridium difficile infection in June 2020. It was agreed that this declaration did not prevent Dr Latimer from participating in this section of the meeting.
	+ 1. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Professor Amanda Adler.
		2. The Chair then asked for the committee, NICE Staff and CDF clinical lead, Professor Peter Clark, to be moved to a closed private session in which confidential information was shared. The company representatives,external group representatives and members of the public remained separate from this closed private session.
		3. All attendees were brought back together, and the Chair continued with presentations on the consultation comments of Apalutamide for treating prostate cancer [ID1534].
	1. Part 2a – Closed session (members of the public and company representatives were asked to leave the meeting. The external group representatives remained).
		1. The committee discussed confidential information submitted for this item.
	2. Part 2b – Closed session (External group representatives were asked to leave the meeting).
		1. The committee then agreed on the content of the Final Appraisal Determination (FAD). The committee decision was reached choose option.
		2. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

### Appraisal of Bimekizumab for treating moderate to severe plaque psoriasis [ID2692]

* 1. Part 1 – Closed session
		1. The Vice Chair welcomed the committee.
		2. The Vice Chair asked all committee members and NICE staff present to declare any relevant interests in relation to the item being considered.
* Prior to the meeting, Dr Laura Bojke, committee member, declared a direct financial interest as she has undertaken consultancy work for Amgen, via a consultancy. This was in a different indication and a different product. It was agreed that this declaration did not prevent Dr Bojke from participating in this section of the meeting.
* Prior to the meeting Dr James Fotheringham, committee member, declared a direct financial interest as he received consultancy and speaker fees from Novartis for promotional activity around a risk prediction tool they are using for a trial currently underway in kidney transplantation. Novartis is a comparator company for this topic. It was agreed that this declaration did not prevent Dr Fotheringham from participating in this section of the meeting.
* Prior to the meeting Dr Nicholas Latimer, committee member, declared a non-financial professional and personal interest as he is a member of the ScHARR team working on an ongoing consultancy project involving the adjustment for treatment switching observed in the NETTER-1 trial, comparing lutathera to best supportive care alone in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumours. Lutathera is made by Advanced Accelerator Applications (AAA) Ltd, a Novartis company. Novartis is a comparator company for this topic. It was agreed that this declaration did not prevent Dr Latimer from participating in this section of the meeting.
	+ 1. The Vice Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Ewa Rupniewska.
	1. Part 2b - Closed session
		1. The committee then agreed on the content of the Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Wednesday 4 August 2021 and will start promptly at 9:30am.